DOI:
10.1055/s-00000105
Zentralblatt für Gynäkologie
LinksClose Window
References
Buzdar AU, Ibrahim NK, Francis D. et al.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomised trial in human epidermal growth factor receptor 2-positive operable breast cancer.
J Clin Oncol 2005; 23: 3676-3682
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.